Roivant Sciences Ltd.
corporate_fare Company Profile
Roivant Sciences Ltd. (NASDAQ:ROIV) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 38 items for ROIV at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for ROIV spans 10-Q, 8-K, 4, 144.
Recent high-impact activity:
- Roivant 10-Q: $4.2B Cash, $191.6M Quarterly Loss, New Immunovant Derivative Suit
- Roivant Q2: LISRAYA Hits $31M in First 5 Weeks; IMVT-1402 Wins D2T RA Endpoint
- Roivant Posts $31M Q2 Revenue, Loss Narrower Than Street Expected
- Roivant's Brepocitinib Meets Primary Endpoint in Both Phase 3 NIU Trials
- Brepocitinib Hits Both Phase 3 Uveitis Trials, Cutting Treatment Failure Risk ~75%
Financial Snapshot
Short Interest & Short Volume
6.07 days to coverFINRA reported short interest of 45,513,591 shares in ROIV as of the October 30, 2026 settlement, a 12.9% increase from the prior period — about 6.1 days to cover at its recent average daily volume. On November 17, 2026, 46.9% of ROIV volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.